Navigating China's technology import and export regulatory framework — from royalty enforcement to post-termination IP protection.
China's technology import and export regime is among the most regulated in the world. Foreign licensors who enter the Chinese market without understanding the regulatory architecture, registration requirements, and enforcement realities face risks that extend well beyond simple contract disputes — including administrative penalties, voided contracts, and irreparable loss of IP rights.
Technology licensing disputes between foreign companies and Chinese counterparties have grown in both frequency and complexity as China has moved from being primarily a technology importer to a dual importer-exporter of advanced technologies. The regulatory framework — anchored by the Regulations on the Administration of Technology Import and Export (the "Technology Import/Export Regulations") and supplemented by the Civil Code (which subsumed the former Contract Law) — imposes mandatory registration, categorization, and approval requirements that have no direct parallel in common law or civil law jurisdictions.
For foreign technology companies, the stakes are particularly high. A poorly structured license can result in the Chinese licensee claiming ownership of improvements, continuing to use the technology after termination, or challenging the validity of royalty obligations. In the worst case, unregistered or improperly categorized technology transfers can be declared void ab initio, stripping the licensor of all contractual protections and exposing it to regulatory sanctions.
Our practice has handled technology licensing disputes across a wide spectrum of industries — from semiconductor fabrication processes and pharmaceutical formulations to industrial automation software and renewable energy technologies. We bring deep familiarity with the regulatory agencies involved, including MOFCOM (Ministry of Commerce) and its local counterparts, and we understand how Chinese courts and arbitral tribunals approach the unique issues that technology licensing disputes present.
The Chinese licensee under-reports sales revenue, excludes certain product lines from the royalty base, applies incorrect exchange rates, or deducts unauthorized costs — all resulting in systematically lower royalty payments. Disputes often center on the scope of the audit clause and whether the licensor can access the licensee's full books and records.
The licensee grants sub-licenses to affiliates, subsidiaries, or third parties without the licensor's consent — or exceeds the territorial, field-of-use, or volume limitations of the original grant. This is especially common in manufacturing licenses where the licensee subcontracts production to related entities.
The technology fails to meet the agreed performance specifications, yield rates, or quality benchmarks during the acceptance testing phase. Disputes arise over whether the deficiency is attributable to the technology itself or to the licensee's inadequate infrastructure, undertrained personnel, or failure to follow protocols.
After the license expires or is terminated for breach, the former licensee continues to use the licensed technology — often under the guise of having independently developed an alternative. Proving continued use and distinguishing it from legitimate independent development is a recurring evidentiary challenge.
Ambiguity in the license grant language leads to disputes over whether the licensee's activities fall within the licensed field of use, territory, or product category. Chinese courts tend to construe ambiguous grant language against the drafter — which is almost always the foreign licensor.
The licensee develops improvements, modifications, or derivative works based on the licensed technology and claims sole ownership — often filing Chinese patents in its own name. The parties' respective rights to improvements are governed by contract and, where the contract is silent, by provisions of the Civil Code that often favor the party that made the improvement.
Under the Technology Import/Export Regulations, contracts for the import of restricted technologies do not take effect until approved by MOFCOM. A contract signed but not yet approved is void — payments made under it may be unrecoverable, and the licensor may have no legal basis to prevent the counterparty from using or disclosing the technology. Foreign licensors must determine the correct classification of their technology before signing, not after.
The Technology Import/Export Regulations divide all technology into three categories. The classification of your technology determines the regulatory pathway, the permissibility of the transfer, and the consequences of non-compliance. Misclassification — whether inadvertent or deliberate — is one of the most serious errors a foreign licensor can make.
| Category | Regulatory Treatment | Contract Effective Date | Key Risk |
|---|---|---|---|
| Prohibited Technologies | Import or export is absolutely forbidden. No license, approval, or registration can overcome the prohibition. | Contract is void ab initio; unenforceable from inception | Criminal liability for parties who knowingly transfer prohibited technology; irrecoverable payments; potential sanctions against both licensor and licensee |
| Restricted Technologies | Import or export requires prior MOFCOM approval. The application must demonstrate that the technology is necessary, that the counterparty is qualified, and that the terms are commercially reasonable. | Takes effect only upon issuance of MOFCOM approval certificate | Contract signed without approval is void; technology disclosed before approval may lose trade secret protection; licensee may use technology without obligation to pay |
| Freely Transferable Technologies | No prior approval required. Contract must be registered with MOFCOM within 60 days of execution for the technology import to be recognized for foreign exchange, tax, and customs purposes. | Effective upon signing by both parties (registration is procedural, not a condition of validity) | Failure to register does not void the contract but blocks foreign exchange remittance of royalties, tax treaty benefits, and customs clearance for related equipment |
The technology catalogue is periodically updated by MOFCOM. What was freely transferable last year may be restricted this year. We recommend a regulatory classification review at the outset of every new China technology transaction — and periodically during the term of long-running licenses — to ensure continuing compliance. A misclassified restricted technology can expose the foreign licensor to administrative fines of RMB 100,000 to 500,000, revocation of business licenses, and in serious cases, criminal prosecution.
The difference between a licensor that can enforce its rights and one that cannot often comes down to the precision of five or six clauses. Below are the provisions that our experience shows are most frequently litigated — and most frequently drafted inadequately.
The license grant must define with precision the licensed technology (including all patents by number, trade secrets by description, and know-how by reference to technical documentation), the licensed field of use, the territory, exclusivity, and any sub-licensing rights. Ambiguity in scope is the single most common source of technology licensing disputes we encounter. A properly drafted scope clause should also address whether the license includes the right to manufacture, have manufactured, use, sell, offer for sale, and import — each right should be separately enumerated.
The acceptance testing procedure must specify objective, measurable criteria, a defined testing period, the party responsible for conducting tests, the documentation each party must provide, and the consequences of failure (including the licensor's right to cure, the licensee's right to terminate, and the treatment of payments made prior to acceptance failure). Chinese courts give substantial weight to the acceptance certificate as evidence that the technology was delivered in conformity with the contract.
The audit clause should entitle the licensor to appoint an independent accountant (preferably from an internationally recognized firm with a China presence) to inspect the licensee's books and records upon reasonable notice, not less than once per year. The clause should specify that the audit covers all records relevant to royalty calculation — including general ledger entries, sales invoices, and subsidiary records — and that if an underpayment exceeding a specified threshold (typically 3-5%) is discovered, the licensee bears the cost of the audit.
The contract must address ownership of improvements made by either party, cross-licensing obligations (if any), and — critically — the licensee's right to file patents on improvements. Without an express provision, Chinese courts have held that a licensee who independently improves the technology owns the improvement. A well-drafted clause should define "improvement," specify ownership allocation, require the licensee to notify and assign, and survive termination.
The termination clause must address the post-termination obligations of the licensee in detail: cessation of use, return or destruction of all technical materials and copies, certification of destruction by an officer, de-installation of software, and — where applicable — the treatment of work-in-progress inventory and after-sale service obligations. A simple "all rights shall cease upon termination" is insufficient; Chinese courts may imply a reasonable wind-down period absent express language to the contrary.
For technology licenses with a Chinese counterparty, the choice of governing law and dispute resolution forum is a threshold strategic decision. Chinese law may be mandatory for restricted technology imports. Where a choice exists, arbitration seated outside China (HKIAC, SIAC) often provides the best balance of enforceability and neutrality. The clause should also address the availability of interim measures, the language of the arbitration, and the number of arbitrators — all matters that, if left to default rules, may disadvantage the foreign party.
Royalty underpayment is the most common technology licensing dispute we encounter. Chinese licensees may under-report sales, misclassify licensed products as non-licensed, apply incorrect pricing formulas, deduct unauthorized costs, or fail to report sales by affiliates and sub-licensees. An effective enforcement strategy combines contractual audit rights, regulatory leverage, and — when necessary — litigation or arbitration.
Invoke the contractual audit right by appointing an independent accounting firm with China operations (e.g., a Big Four firm). Provide formal written notice to the licensee specifying the audit scope, period, and proposed timing. Under Chinese law, the licensee is obligated to cooperate with a properly invoked contractual audit — refusal to provide books and records can itself constitute a breach and strengthen the licensor's position in subsequent proceedings.
Where the contractual audit reveals discrepancies or the licensee refuses to cooperate, escalate to forensic investigation. This may involve comparing the licensee's reported sales data against customs export records, VAT invoices (fapiao), tax filings, and public filings of listed parent companies. In our experience, the most significant underpayments are discovered not through the audit process itself but through the forensic cross-referencing that follows.
Present the audit findings in a formal demand letter setting out the underpaid amounts, the calculation methodology, interest claimed, and a reasonable deadline for payment. In many cases, the combination of a well-documented audit and the implicit threat of litigation is sufficient to bring the licensee to the negotiating table. Structured settlement negotiations at this stage can preserve the commercial relationship while recovering the underpaid royalties.
If the licensee refuses to pay or attempts to dissipate assets, apply to the competent court or arbitral tribunal for property preservation orders (asset freezing orders) against the licensee's bank accounts, receivables, and real property. Chinese courts can grant such orders ex parte in urgent cases, and they are a powerful tool to concentrate the licensee's mind on settlement.
Commence formal proceedings before the agreed forum — typically CIETAC, HKIAC, or SIAC for international technology licensing disputes. The key evidence will be the audit report, the forensic analysis, and the contemporaneous correspondence between the parties. Chinese arbitral tribunals have shown increasing willingness to award full underpaid royalties plus interest, audit costs, and — in cases of bad faith — a significant proportion of the prevailing party's legal costs.
Enforce the award or judgment against the licensee's assets in China and, where applicable, in other jurisdictions under the New York Convention. Where the licensee is part of a larger corporate group, consider whether the parent company can be joined or whether the corporate veil can be pierced under Chinese law to reach group assets — a developing but increasingly viable avenue in Chinese jurisprudence.
We bring a three-pronged approach to every technology licensing engagement — structuring the transaction for enforceability, enforcing audit rights to capture full value, and securing post-termination remedies to prevent ongoing misuse of your IP.
We draft and review technology license agreements with a focus on provisions that withstand scrutiny before Chinese courts and arbitral tribunals. This includes precise scope definitions, robust audit clauses, clear improvement ownership provisions, and enforceable termination consequences. We also advise on the structuring of royalty formulas — lump sum versus running royalty, minimum royalty floors, and inflation adjustment mechanisms — to minimize the opportunities for underpayment and maximize the licensor's recovery position in the event of a dispute.
When royalty underpayment is suspected, we deploy a coordinated strategy combining contractual audit rights, forensic accounting, and — where necessary — regulatory pressure. Our team works with major international accounting firms and local forensic specialists to conduct audits that produce evidence admissible in Chinese courts and arbitral tribunals. We have recovered substantial underpaid royalties for clients in the pharmaceutical, semiconductor, and industrial equipment sectors.
The period immediately following termination is when a licensor's IP is most vulnerable. We assist clients in obtaining and enforcing cease-and-desist orders, securing the return or destruction of technical materials, and — where the former licensee continues to use the technology — pursuing claims for post-termination infringement and unjust enrichment. We also coordinate with customs authorities to block the export of products manufactured using misappropriated technology.
Represented a European pharmaceutical company in a royalty audit and enforcement action against its Chinese manufacturing licensee. The audit revealed systematic under-reporting of production volumes over a four-year period, resulting in underpaid royalties exceeding RMB 80 million. After obtaining interim asset preservation orders, we secured a favorable settlement that recovered the full underpaid amount plus interest and audit costs, and restructured the license agreement with enhanced audit provisions.
Never rely on a handshake, a relationship, or a "standard international form" agreement. Chinese technology licensing is a regulated activity — the contract must be purpose-built for Chinese law, registered where required, and enforced proactively. The cost of getting it right at the outset is a fraction of the cost of litigating a poorly structured license after the relationship has broken down.
Whether you are structuring a new technology license, pursuing underpaid royalties, or enforcing post-termination remedies, we bring the regulatory knowledge and litigation experience to protect your most valuable assets. Your initial consultation is confidential.
Schedule a Consultation